Anti Inflammatory News and Research

RSS

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that a settlement agreement with certain former shareholders and directors of Jiangsu Quanyi Biological Technology Stock Co., Ltd. has become effective.

7 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Nano-formulated indomethacin at lower dose effective in treating pain

A novel, lower-dose formulation of indomethacin, a widely used pain reliever, is absorbed faster by the body than a standard formulation and maintains comparable maximum concentrations in the blood despite being administered at a lower dose, according to a study to be reported here tomorrow at the annual meeting of the American Headache Society.

4 Jun 2011

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

One of the beneficial compounds found in green tea has a powerful ability to increase the number of "regulatory T cells" that play a key role in immune function and suppression of autoimmune disease, according to new research in the Linus Pauling Institute at Oregon State University.

3 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Possible defense for community-acquired pneumonia among the elderly

Community-acquired pneumonia is the leading cause of infectious death among the elderly. Newly published research from The University of Texas Health Science Center San Antonio suggests why older people are vulnerable and offers a possible defense.

27 May 2011

Lactate shuttle also exists in human tumors

Researchers at the Kimmel Cancer Center at Jefferson have shed new light on the longstanding conundrum about what makes a tumor grow-and how to make it stop. Interestingly, cancer cells accelerate the aging of nearby connective tissue cells to cause inflammation, which ultimately provides "fuel" for the tumor to grow and even metastasize.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Research sheds light on how painkillers could prevent or slow down cancer growth

CANCER RESEARCH UK scientists have shed light on how a common class of painkillers - which includes ibuprofen - may interact with a key protein that fuels the growth of many different types of cancer, according to a study published in the journal Chemical Communications today.

27 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Novartis announced results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid used to treat gouty arthritis attacks.

25 May 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

Researchers replicate progression of inflammatory gene changes of kidney from mild to severe diabetic nephropathy

University of Louisville researchers have replicated the inflammatory gene changes of a human kidney as it progresses from mild to severe diabetic nephropathy, using a mouse model developed by a UofL researcher, according to an article published today in the journal Experimental Nephrology. Diabetic nephropathy is the foremost cause of kidney failure.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.

24 May 2011

Substantial portion of patients with headaches improve without treatment

Headache is a very common complaint, with over 90% of all persons experiencing a headache at some time in their lives. Headaches commonly are tension-type (TTH) or migraine. They have high socioeconomic impact and can disturb most daily activities. Treatments range from pharmacologic to behavioral interventions.

23 May 2011

Novel compound could become an effective alternative to common narcotic analgesics

Scientists from the Florida campus of The Scripps Research Institute have for the first time accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine.

23 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

Anti Inflammatory News and Research

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Nano-formulated indomethacin at lower dose effective in treating pain

Green tea consumption increases number of 'regulatory T cells', prevents autoimmune disease

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Possible defense for community-acquired pneumonia among the elderly

Lactate shuttle also exists in human tumors

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Research sheds light on how painkillers could prevent or slow down cancer growth

Lx Therapies, BioCis partner to form Laurantis Pharma

Two Novartis ACZ885 Phase III trial data in severe gouty arthritis to be presented at EULAR 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Researchers replicate progression of inflammatory gene changes of kidney from mild to severe diabetic nephropathy

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

Substantial portion of patients with headaches improve without treatment

Novel compound could become an effective alternative to common narcotic analgesics

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News